Chronic Total Occlusion Stenting
Baylor Hamilton Heart and Vascular Hospital is a referral center for highrisk patients with coronary artery disease seeking treatment for totally occluded arteries with chronic total occlusion( CTO) stenting. An option to bypass surgery or traditional stenting, interventional cardiologists thread a wire catheter against the standard flow of blood in the artery to the site of the blockage. Traditionally, total blockages of the coronary artery have been difficult to clear with interventional procedures. New technology makes fine movement of the guide wire tip much easier to control than in the past. Baylor Hamilton Heart and Vascular Hospital is among just a handful of facilities in Texas offering this service to address coronary obstructions.
In the last few years, the success rate of the combined percutaneous approach has increased from about 60 percent to more than 85 percent. This is in comparison to the success rate of about 98 percent for percutaneous treatment of non-total blockages. Although the percutaneous approach has potential complications, the complication rate is comparable to that of standard angioplasty( about 1 percent).
In addition to being one of the highest volume CTO cardiac centers in the nation, the hospital is also dedicated to research and innovation. Baylor Hamilton Heart and Vascular Hospital is participating in the CTO Progress Registry, a national database of elite cardiac centers nationwide that share data to identify best practices and best outcomes, and patients benefit from CTOrelated studies including various research trials to drive innovation. As one of four participating organizations in Texas, it is an honor for the hospital and participation differentiates the program’ s capabilities from many others.
132
Total
Image courtesy of Medtronic
CTOs performed at Baylor Hamilton Heart and Vascular Hospital in Dallas
( FY17)
Baylor Hamilton Heart and Vascular Hospital participated in this registry( FY17)
FIRST IN TEXAS: RESOLUTE ONYX ™ DRUG- ELUTING STENT
Baylor Hamilton Heart and Vascular Hospital became the first hospital in Texas and second in the U. S. to implant a next generation stent unlike others available. The latest advance in drug-eluting stents, the Medtronic Resolute Onyx™ Drug-Eluting Stent, was FDA approved in early May 2017 to treat coronary artery disease.
Resolute Onyx drug-eluting stent offers the widest range of sizes, expanding the treatment options available for patients. The technology of the stent’ s structure allows for greater flexibility as the stent is placed inside a patient’ s artery by an interventional cardiologist. The sizes offered also allow for larger size vessels, which is unique to this particular stent.
“ If you have coronary artery disease and need treatment, interventional cardiologists on the medical staff at Baylor University Medical Center at Dallas have access to advances in drug-eluting stent technology, which offers better treatment options to more patients,” says Kevin Wheelan, MD, chief of medical staff at Baylor Hamilton Heart and Vascular Hospital.“ Keeping with the tradition of advancing cardiovascular treatment, we are proud to offer this latest generation drug-eluting stent to patients.”
“ One of the unique key features to the Onyx drug-eluting stent is the deliverability of the stent especially for larger vessels sized 4.0 or 5.0 mm. This flexibility is important in the newest generation of drug eluting stents,” says Robert Stoler, MD, FACC, FSCAI, medical director for cardiac catheterization.“ The stent was designed for PCI using the transradial approach, giving interventional cardiologists multiple options for their patients.”
Interventional Cardiology
OUTCOMES 2017
33